Requip Xl
(Ropinirole)ApprovedSmall molecule
Requip Xl is a small molecule that works as a D2-Like Dopamine Receptor Agonist.[2] It is being used across 6 indications, with its most advanced program in Approved.[1]
Requip Xl is one of 133 small molecule programs targeting Parkinson disease. It is currently in Approved.
6
Indications
42
Total Trials
0
Active Trials
132
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
120 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Requip Xl
GGlaxo Dba Glaxosmithkline
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Clozaril
LLife Extension Foundation Inc.
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Sunosi
AAxsome Therapeutics, Inc.
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
Aticaprant
Johnson & JohnsonPhase 3
Selective Serotonin Reuptake Inhibitor
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Restless Legs Syndrome12 trials
Show 9 more trials
Parkinson's Disease7 trials
Show 4 more trials
Bipolar Depression2 trials
Parkinson's2 trials
16 more indications
Hyperprolactinemia1 trial
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
Completed·—·Phase 1/2·NCT03038308·16 enrolled
Chronic Kidney Disease1 trial
Sexual Dysfunction1 trial
Adult1 trial
Parkinson's Disease (PD)1 trial
Myoclonic Epilepsy1 trial
Absorption1 trial
Complication1 trial
End-Stage Renal Disease1 trial
TED1 trial
Effectiveness1 trial
Fed1 trial
Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fed Condition
Completed·—·Phase 1·NCT01627847·48 enrolled
Unspecified2 trials
Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fasting Condition
Completed·—·Phase 1·NCT01627834·48 enrolled
Regulatory
FDA Approval Timeline[4]
Sep 19, 1997
REQUIP
NDA NDA020658
Jun 13, 2008
REQUIP XL
NDA NDA022008
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ropinirole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- D2-Like Dopamine Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- GGlaxo Dba Glaxosmithkline